Intellia Therapeutics’ stock rocked by patient death in gene therapy trial
A patient dosed with Intellia Therapeutics’ CRISPR gene therapy has died after suffering a severe liver-associated adverse event (AE). The patient had been dosed with nex-z (nexiguran ziclumeran) in the Phase III MAGNITUDE trial (NCT06128629) on 30 …